Congratulations! Innocare‘s Orelabrutinib has been approved by NMPA for Commercial in China!
InnoCare Pharma's BTK inhibitor, Orelabrutinib, receives NMPA approval for commercialization in China, targeting mantle cell lymphoma and chronic lymphocytic ...
November 22, 2020